Tradestie Institutional Equity Comparison Engine
NBIX vs OKYO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NBIX Overall Edge
NBIX Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Neurocrine Biosciences Inc (NBIX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NBIX trades at 12.2x Forward P/E with 26.6% operating margin (+41.2% YoY revenue) versus OKYO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NBIX sits in CONSOLIDATION (26th %ile IV; Dealer Gamma Walls on Pro) against OKYO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
NBIX
NBIX 12.2x vs OKYO N/M Fwd P/E
Growth & Margin Winner
NBIX
Op Margin 26.6% vs 0.0% ยท YoY +41.2% vs +0.0%
Momentum & Technical Winner
NBIX
1Y +9.1% vs -47.0% ยท 52W Pos 44% vs 3%
Options & Structure Winner
NBIX
CONSOLIDATION (26th %ile IV) vs UNCLASSIFIED (N/A IV)
NBIX
NASDAQ
Neurocrine Biosciences Inc
Biological Products, (No Disgnostic Substances)
$150.57
-3.84% 1D
Market Cap
$15.8B
1M Return
+5.08%
1Y Return
+9.06%
Forward P/E
12.2x
Unified AI Score
40.0 / 100
SELL
Tech 20.0
Fund 46.0
Flow 67.0
Mom 60.0
OKYO
NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap
$62.7M
1M Return
-27.21%
1Y Return
-47.03%
Forward P/E
N/M
Unified AI Score
42.8 / 100
HOLD
Tech 38.0
Fund 54.0
Flow 50.0
Mom 45.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NBIX +9.06%
OKYO -47.03%
Spread: +56.09 pp (NBIX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NBIX TTM Op. Margin: 26.6%
OKYO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBIX vs OKYO. Trailing 12-month operating profitability (NBIX 26.6% vs OKYO 0.0%) and valuation multiples (NBIX 12.2x vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NBIX | OKYO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.8B | $62.7M | Larger Scale | NBIX |
| Trailing P/E Ratio Valuation | 24.2x | N/M | Lower Multiple | NBIX |
| Forward P/E Ratio Valuation | 12.2x | N/M | Lower Multiple | NBIX |
| Revenue Growth (YoY) Growth | +41.2% | +0.0% | Higher Growth | NBIX |
| Operating Margin (TTM) Profitability | 26.6% | 0.0% | Higher Margin | NBIX |
| Net Profit Margin Profitability | 19.0% | 0.0% | Higher Margin | NBIX |
| Return on Equity (ROE) Capital Efficiency | 20.4% | -263.8% | Higher ROE | NBIX |
| 52-Week Range Position Momentum | 44% ($122โ$186) | 3% ($1โ$3) | Stronger Trend | NBIX |
| Beta / 30D Volatility Risk Regime | 0.67ฮฒ ยท 56% Vol | 1.00ฮฒ ยท 76% Vol | Lower Realized Risk | NBIX |
| Unified Institutional Score Composite Signal | 40.0 / 100 (SELL) | 42.8 / 100 (HOLD) | Higher Composite | OKYO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NBIX vs OKYO Buy Guide
NBIX
CONSOLIDATION
95d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
OKYO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NBIX nor OKYO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.